Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer

Date

21 Sep 2020

Session

Proffered Paper - Supportive and palliative care

Presenters

Omer Dizdar

Citation

Annals of Oncology (2020) 31 (suppl_4): S874-S880. 10.1016/annonc/annonc264

Authors

O. Dizdar1, O. Bas2, A. Erdemir3, R. onur3, G. Guner1, D.C. Guven1, S. aksu4, N. Kertmen1, S. Aksoy1, I. barista1, A. Turker1

Author affiliations

  • 1 Department Of Medical Oncology, Hacettepe University Cancer Institute, 06100 - Ankara/TR
  • 2 Internal Medicine, Hacettepe University - Faculty of Medicine, 06100 - Ankara/TR
  • 3 Radiology, Hacettepe University - Faculty of Medicine, 06100 - Ankara/TR
  • 4 Department Of Haematology, Hacettepe University Faculty of Medicine, 06100 - Ankara/TR
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1504O

Background

sarcopenia is associated with poor prognosis and increased treatment toxicity in patients with cancer. However, there is limited data about sarcopenia and cardiotoxicity of chemotherapy. The aim of this study is to evaluate relationship between sarcopenia and anthracycline (AC) related cardiotoxicity.

Methods

Patients who received AC-based chemotherapy between 2014-2018, and had baseline abdominal CT containing both L3-L4 levels for measuring skeletal muscle index (L3-L4 SMI) and psoas muscle index (PMI), and baseline and follow-up echocardiography after AC treatment were included. Sex-specific cutoffs for L3 SMI, L4 SMI and PMI were used for diagnosis of sarcopenia. Cardiotoxicity was defined as development of either systolic dysfunction according to European society of Cardiology (ESC) ejection fraction (EF) criteria, or diastolic dysfunction according to American Society of Echocardiography (ASE) diastolic dysfunction criteria. Multivariate analysis was performed to determine potential predictors of cardiotoxicity.

Results

A total of 166 patients (75 male, 91 female) were included; 50 (30.1 %) with breast cancer, 82 (49.4 %) with lymphoma, 11 (6.6 %) with sarcoma and 23 (13.9%) with other cancers. Median age was 48 years and median doxorubicin dose was 238 mg/m2. Sarcopenia was determined in 33 (19.9 %) according to L3 SMI, in 17 (10.2 %) according to L4 SMI and in 45 (27.1 %) according to PMI. After AC treatment, 27 patients (16.3 %) developed cardiotoxicity; 17 (10.2 %) had systolic dysfunction, 9 (5.4%) had diastolic dysfunction and 1 (0.6 %) had both. After adjustment for age, gender, doxorubicin dose, body mass index, and presence of cardiovascular disease; sarcopenia at any of the three levels was significantly associated with increased risk of cardiotoxicity. (L3 SMI Hazard ratio [HR]= 4.14, 95% confidence interval [CI] 1.66-10.31, p=0.002; L4 SMI HR= 3.65, 95% CI 1.21-11.0, p=0.022; PMI HR= 4.39, 95% CI 1.81-10.65, p=0.001).

Conclusions

This is the first study demonstrating a significant association between CT-based diagnosis of sarcopenia and anthracycline-related cardiotoxicity. Routine CT scans may help clinicians identify high risk patients in whom closer follow-up or cardioprotective measures should be considered.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest..

Resources from the same session

Q&A and live discussion

Presenter: Stein Kaasa

Session: Proffered Paper - Supportive and palliative care

Resources:

Webcast

Q&A and live discussion

Presenter: Stein Kaasa

Session: Proffered Paper - Supportive and palliative care

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings